XGN vs. LFMD, TALK, INNV, EHAB, SBC, AUNA, CSTL, CELC, PSNL, and FTRE
Should you be buying Exagen stock or one of its competitors? The main competitors of Exagen include LifeMD (LFMD), Talkspace (TALK), InnovAge (INNV), Enhabit (EHAB), SBC Medical Group (SBC), Auna (AUNA), Castle Biosciences (CSTL), Celcuity (CELC), Personalis (PSNL), and Fortrea (FTRE). These companies are all part of the "healthcare" industry.
Exagen vs. Its Competitors
Exagen (NASDAQ:XGN) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.
LifeMD received 12 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 76.92% of users gave LifeMD an outperform vote while only 62.22% of users gave Exagen an outperform vote.
Exagen presently has a consensus price target of $7.50, suggesting a potential upside of 3.95%. LifeMD has a consensus price target of $11.00, suggesting a potential downside of 12.25%. Given Exagen's higher probable upside, analysts clearly believe Exagen is more favorable than LifeMD.
Exagen has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, LifeMD has a beta of 2.42, indicating that its stock price is 142% more volatile than the S&P 500.
75.3% of Exagen shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 12.6% of Exagen shares are owned by insiders. Comparatively, 18.4% of LifeMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
LifeMD has a net margin of -12.06% compared to Exagen's net margin of -30.36%. LifeMD's return on equity of 0.00% beat Exagen's return on equity.
LifeMD has higher revenue and earnings than Exagen. LifeMD is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.
In the previous week, LifeMD had 4 more articles in the media than Exagen. MarketBeat recorded 6 mentions for LifeMD and 2 mentions for Exagen. LifeMD's average media sentiment score of 1.17 beat Exagen's score of 0.94 indicating that LifeMD is being referred to more favorably in the news media.
Summary
LifeMD beats Exagen on 12 of the 18 factors compared between the two stocks.
Get Exagen News Delivered to You Automatically
Sign up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NASDAQ:XGN) was last updated on 6/12/2025 by MarketBeat.com Staff
